{
    "clinical_study": {
        "@rank": "92250", 
        "arm_group": [
            {
                "arm_group_label": "bimatoprost formulation A solution", 
                "arm_group_type": "Experimental", 
                "description": "Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator."
            }, 
            {
                "arm_group_label": "bimatoprost solution 0.03 %", 
                "arm_group_type": "Active Comparator", 
                "description": "Bimatoprost solution 0.03 % (LATISSE\u00ae) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator."
            }, 
            {
                "arm_group_label": "vehicle of bimatoprost formulation A solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator."
            }, 
            {
                "arm_group_label": "vehicle of bimatoprost solution 0.03 %", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of bimatoprost solution formulation A\n      compared with bimatoprost solution 0.03% (LATISSE\u00ae) and vehicle in the treatment of eyelash\n      hypotrichosis (inadequate eyelashes)."
        }, 
        "brief_title": "Bimatoprost in the Treatment of Eyelash Hypotrichosis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Idiopathic Eyelash Hypotrichosis", 
        "condition_browse": {
            "mesh_term": "Hypotrichosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mild to moderate eyelash hypotrichosis (inadequate eyelashes)\n\n        Exclusion Criteria:\n\n          -  Damage to eyelid area (scarring) that may prevent growth of eyelashes\n\n          -  Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe\n             dry eye)\n\n          -  Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery,\n             blepharoplasty) during the 3 months prior to screening\n\n          -  Current eyelash implants of any kind\n\n          -  Eyelash tint or dye application within 2 months of baseline\n\n          -  Eyelash extensions application within 3 months of baseline\n\n          -  Use of eyelash growth products within 6 months of baseline\n\n          -  Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents,\n             etc) within 6 months prior to baseline"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "464", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698554", 
            "org_study_id": "192024-046", 
            "secondary_id": "2012-003007-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "bimatoprost formulation A solution", 
                "description": "Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.", 
                "intervention_name": "bimatoprost formulation A solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bimatoprost solution 0.03 %", 
                "description": "Bimatoprost solution 0.03 % (LATISSE\u00ae) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.", 
                "intervention_name": "bimatoprost solution 0.03 %", 
                "intervention_type": "Drug", 
                "other_name": "LATISSE\u00ae"
            }, 
            {
                "arm_group_label": "vehicle of bimatoprost formulation A solution", 
                "description": "Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.", 
                "intervention_name": "vehicle of bimatoprost formulation A solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "vehicle of bimatoprost solution 0.03 %", 
                "description": "Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.", 
                "intervention_name": "vehicle of bimatoprost solution 0.03 %", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United Kingdom", 
                        "state": "England"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Russian Federation", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Investigator's Assessment of Overall Eyelash Prominence as Measured by the 4-point Global Eyelash Assessment (GEA) Scale", 
            "safety_issue": "No", 
            "time_frame": "Month 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)", 
                "safety_issue": "No", 
                "time_frame": "Month 4"
            }, 
            {
                "measure": "Upper Eyelash Thickness/Fullness as Measured Using DIA", 
                "safety_issue": "No", 
                "time_frame": "Month 4"
            }, 
            {
                "measure": "Upper Eyelash Intensity (Darkness) as Measured Using DIA", 
                "safety_issue": "No", 
                "time_frame": "Month 4"
            }, 
            {
                "measure": "Patient's Assessment of Overall Eyelash Satisfaction as Measured by the 9-item Eyelash Satisfaction Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Month 4"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}